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Abstract
About 80% of colorectal cancers (CRCs) have chromosomal instability, which is an integral part of aggressive malignancy
development, but the importance of specific copy number aberrations (CNAs) in modulating gene expression, particularly
within the framework of clinically relevant molecular subtypes, remains mostly elusive. We performed DNA copy number
profiling of 257 stage I-IV primary CRCs and integrative gene expression analysis in 151 microsatellite stable (MSS)
tumors, focusing on high-level amplifications and the effect of CNAs on the characteristics of the gene expression-based
consensus molecular subtypes (CMS). The results were validated in 323 MSS tumors from TCGA. Novel recurrent high-
level amplifications (≥15 additional copies) with a major impact on gene expression were found for TOX3 (16q) at 1.5%
frequency, as well as for CCND2 (12p) and ANXA11 (10q) at 1% frequency, in addition to the well-known targets ERBB2
(17q) and MYC (8q). Focal amplifications with ≥15 or ≥5 additional copies of at least one of these regions were associated
with a poor overall survival among patients with stage I-III MSS CRCs (multivariable hazard ratio ≥3.2, p ≤ 0.01). All high-
level amplifications were focal and had a more consistent relationship with gene expression than lower amplitude and/or
broad-range amplifications, suggesting specific targeting during carcinogenesis. Genome-wide, copy number driven gene
expression was enriched for pathways characteristic of the CMS2-epithelial/canonical subtype, including DNA repair and
cell cycle progression. Furthermore, 50% of upregulated genes in CMS2-epithelial/canonical MSS CRCs were driven by
CNAs, an enrichment compared with the other CMS groups, and associated with the stronger correspondence between
CNAs and gene expression in malignant epithelial cells than in the cells of the tumor microenvironment (fibroblasts,
endothelial cells, leukocytes). In conclusion, we identify novel recurrent amplifications with impact on gene expression in
CRC and provide the first evidence that CMS2 may have a stronger copy-number related genetic basis than subtypes more
heavily influenced by gene expression signals from the tumor microenvironment.
Introduction
Colorectal cancers (CRC) can be classified into four bio-
logically distinct and clinically relevant consensus mole-
cular subtypes (CMS) based on their global gene expression
patterns [1]. A few genetic associations to the specific CMS
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groups have been reported, such as microsatellite instability
(MSI) and BRAF mutation in CMS1 and KRAS mutation in
CMS3, and the low frequency of somatic copy number
aberrations (CNAs) in MSI is well established. However,
little is in general known about the genetic basis for the
distinct gene expression-based subtypes.
Chromosomal instability is an integral part of canonical
CRC pathogenesis, and the majority of CRCs are char-
acterized by a large burden of CNAs. Chromosomal
instability is associated with poor patient prognosis [2] and
resistance to multiple drugs [3]. Although the frequencies of
individual CNAs in CRC are well studied [4], it remains
challenging to distinguish CNAs with impact on tumor
growth from passenger events that accumulate as a con-
sequence of chromosomal instability. Although the chro-
mosome instability phenotype is clearly distinct from the
MSI phenotype, which is characterized by frequent single-
nucleotide variants and small insertions and deletions, there
is a large extent of molecular heterogeneity among chro-
mosomally instable tumors.
Known recurrent amplification events are few and of low
prevalence in CRC, but may have major impact on preci-
sion medicine. The HER2 protein, which is upregulated as a
result of high-level ERBB2 amplification, is a druggable
target, and the HERACLES trial demonstrated a 30%
response rate to dual HER2 blockade in the 5% sub-
population of HER2 positive and KRAS wild-type meta-
static cancers [5]. Furthermore, FGFR2 amplifications are
potentially druggable [6, 7], and KRAS amplifications may
predict lack of response to EGFR blockade [8]. Con-
sistently, the clinical relevance of these amplification events
is dependent on subsequent upregulation of the gene pro-
duct, highlighting the importance of integrative DNA copy
number and gene expression analyses.
Gene expression profiles of two of the CMS groups,
CMS1-MSI/immune and CMS4-mesenchymal, are heavily
influenced by signals from non-malignant cells in the tumor
microenvironment, while the profiles of CMS2-epithelial/
canonical and CMS3-epithelial/metabolic are largely shaped
by cancer cell-intrinsic signals. Consequently, CNAs may
have larger effects on gene expression profiles in CMS2
and CMS3.
Here we integrate DNA copy number and gene expres-
sion data in primary CRCs to i) identify novel recurrent
amplifications with a strong impact on gene expression, and
ii) reveal copy number aberrations associated with the dis-
tinct gene expression profiles of the individual CMS groups.
Results
Consistent with the mutation phenotypes, high-resolution
DNA copy number profiles from 257 stage I-IV primary
CRCs confirmed that MSS tumors (n= 203) had sig-
nificantly more CNAs and loss of heterozygosity (LOH)
than MSI (n= 53) or MSS POLE (n= 1) mutated tumors,
and the genome-wide frequency of copy number gains and
losses recapitulated findings from previous studies (Sup-
plementary Fig. 1a–d). Target genes of focal gains and
losses in MSS tumors were found in 25 and 37 chromo-
somal regions, respectively (GISTIC; q < 0.25; Supple-
mentary Table 1), and included a wide range of cancer-
critical genes (Cosmic Cancer Gene Census), such as gain
of ERBB2, FGFR1, FLT3, CCND2, ERC1 and CDX2, and
loss of SMAD4, FAS, PTEN and APC.
Novel recurrent high-level amplifications in CRC
Approximately half of the MSS tumors (103/203; 51%) had
at least one amplification event (median one event per
tumor, range 0–25 events; Supplementary Fig. 2a), and this
was associated with ploidy, but not with tumor stage
(Fig. 1a and Supplementary Fig. 2b). Among high-ploidy
tumors (≥2.2n), 74% (86 of 118 tumors) had at least one
amplification event, compared with 20% among low-ploidy
tumors (17 of 85 tumors with <2.2n).
Amplifications were most frequently seen on 8q, 13q and
20q, which were often affected by broad amplifications
(6%, 12% and 14% of amplifications encompassed >200
genes, respectively; Supplementary Fig. 3a–c). A compar-
ison of the number of genes encoded in each amplified peak
and the respective amplification amplitude revealed a dis-
tinct separation at approximately 50 genes and 15 additional
DNA copies, showing that all high-level amplifications
(defined as ≥15 additional copies) were focal (encoding ≤ 50
genes; Fig. 1b). Totally, 22 (11%) of the MSS tumors had
high-level focal amplifications, but each event was of low
frequency. The most prevalent events were recurrent in
three tumors each (1.5%) and affected a region on 17q12-
q21.1, confirming the existence of a CRC subgroup with
extreme ERBB2 amplification (22, 27 and 97 additional
copies), and a region on 16q12.1–12.2 (23, 44 and 47
additional copies), identifying CASC16 and the transcrip-
tion factor TOX3 as novel recurrently amplified genes
(Table 1, Fig. 1c, Supplementary Fig. 2e). In addition to the
three tumors with high-level amplifications of TOX3/
CASC16, another three tumors had focal amplifications with
5–14 additional copies of this region, resulting in a total
amplification frequency of 3% (≥5 additional copies, 6/203
tumors). Three other high-level amplifications covering
MYC, CCND2, and a region on 10q22.3-q23.1 were
recurrent in two samples each (1%). Among stage I-III MSS
CRCs, patients with high-level focal amplifications (≥15
additional copies) of either of the five recurrent regions
(n= 10 patients) had a significantly poorer 5-year overall
survival rate than the patients without an amplification (40%
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Fig. 1 Recurrent high-level amplifications in CRC (a) The fraction of
tumors with at least one amplification event was not associated with
stage, but was substantially higher in high-ploidy tumors compared to
low-ploidy tumors. b We identified a clear separation between focal
and broad amplifications at approximately 15 additional copies and 50
genes in peak. Focal amplifications were distributed across multiple
chromosomes (zoomed). c On five of the chromosomes with recurrent
focal high-level amplifications (≥15 additional copies, <50 genes in
peak), additional tumors had focal amplifications with ≥5 additional
copies. Including all these amplicons, the amplification frequency was
1.5% (three tumors) for ANXA11 (10q), CCND2 (12p) and ERBB2
(17q); 2.5% (five tumors) forMYC (8q); and 3% (six tumors) for TOX3
(16q). Combined survival analysis showed that the 16 stage I-III MSS
patients displaying focal amplifications (with ≥5 additional copies) in
either of the five genes demonstrated a significant association to poor
patient outcome. Chromosome plots: Left y-axis: number of additional
copies above median copy number (different colored lines represent
different tumors). Right y-axis: the percentage of samples with gain in
the region of interest, visualized as a light pink band behind the lines
indicating individual tumors
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versus 71%, p= 0.03, log rank test). The amplification had
independent prognostic value in multivariable analysis
including patient age and gender, and tumor localization
and stage (hazard ratio [HR] 3.2, 95% confidence interval
[CI] 1.3–7.9, p= 0.01). Similar results were found when
including patients with focal amplifications with ≥5 addi-
tional copies of these regions in the analyses (total n= 16
patients; Fig. 1c; univariable HR 3.0, 95% CI 1.5–5.9, p=
0.002, multivariable HR 3.3, 95% CI 1.6–6.8, p= 0.001;
Supplementary Table 2). Of note, neither overall CNA
levels, nor the presence of any focal amplification on the ≥5
or ≥15 additional copies levels were associated with poor
outcome (p > 0.18 in univariable Cox regression). All
recurrent amplifications were validated in MSS CRCs from
TCGA (Table 1). Furthermore, several cancer-critical genes
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inhouse dataset and among these, amplifications of CDX2
were particularly prevalent in the TCGA cohort, with a
1.6% prevalence of focal high-level amplifications and a
prevalence of 4.7% when also including low-level
amplifications.
Heterogeneity in gene expression concordance of
copy number aberrations
Amplification events are expected to have strong effects on
gene expression, and 40% of the high-level focal amplifi-
cation peaks (≥15 additional copies) were associated with
outlier expression (defined as >1.5 interquartile range above
the third quartile) of at least one affected gene. Moreover,
for 76% of the 34 genes with recurrent high-level focal
amplifications, the gene expression levels in the affected
samples were among the highest in the cohort (see Materials
and Methods for criteria). However, including also
intermediate-level (≥5 additional copies) and both broad and
focal amplification events, no more than 35% (389 of 1096)
of recurrently amplified genes had corresponding high gene
expression. This indicates a heterogeneous effect of ampli-
fications on gene expression, supporting the expectation that
high-level and focal amplifications have the largest impact.
With respect to the most recurrent amplifications (≥5
additional copies), ERBB2 amplified tumors had sig-
nificantly higher expression of both ERBB2 and other
affected genes in this region, and five TOX3 amplified
tumors with available gene expression data had significantly
higher expression than non-amplified tumors (Fig. 2a).
Amplifications in CCND2 and MYC also had significant
impact on gene expression. Furthermore, ANXA11 was
nominated as a likely target of the 10q22.3-q23.1 amplifi-
cation, based on outlier gene expression in the two analyzed
tumors (Fig. 2a). Amplification-associated expression of
these genes was also validated in the TCGA tumors, and
across both datasets, the increase in gene expression was
regardless of CMS subtype (Fig. 2a, Supplementary Fig. 4a).
Genome-wide integration analyses were also performed
for recurrent copy number gains and losses (≥10 tumors and
with gene expression variance > 0.1). Within the MSS sub-
group, 35% of genes with copy number gain (2467 of 7091
genes) and 45% of genes with copy number loss (3080 of
6861 genes) had concomitant upregulated or downregulated
gene expression, respectively (false discovery rate, FDR,
adjusted p < 0.05, Wilcoxon rank-sum test; Spearman’s rho
> 0 and FDR adjusted p < 0.05, Spearman correlation test;
Fig. 2b). In the gain/upregulation category, 4.7% (117
genes) were cancer-critical and 2.1% (53 genes) were clas-
sified as oncogenes in MSigDB, among them 15 transcrip-
tion factors and seven protein kinases (Fig. 2c). Also, 2%
(50 genes) were related to DNA-repair, and analyses of
pathway overrepresentation (Reactome database) showed a
significant enrichment of pathways related to homologous
DNA repair and cell cycle when considering genes dis-
playing the largest increase in median gene expression in
tumors with gain compared to neutral copy number (Sup-
plementary Table 3). Among genes with loss/down-
regulation, 4.2% (129 genes) were cancer-critical and 0.8%
(25 genes) were classified as tumor suppressors in MSigDB,
including TP53, APC, SMARCB1 and SMAD4 and several
genes related to differentiation (CDH1, BMPR1A and FAS).
Considering the association between amplification events
and a high tumor ploidy, gene set enrichment analyses were
also performed in relation to ploidy. This revealed that high-
ploidy tumors had upregulation of gene sets related to cell
cycle checkpoints, WNT signaling, MYC targets and DNA
repair, and downregulation of gene sets related to metabolism,
immune response and IL6-JAK-STAT3 signaling (GSA, p <
0.2; Fig. 2d). These processes are CMS-associated, with
upregulated gene sets being characteristic of CMS2 and
downregulated gene sets of CMS3 and CMS1, indicating a
potential link between DNA copy numbers, gene expression
and CMS. This was also in line with an observed enrichment
of CMS2 tumors in the high-ploidy group (Fig. 2e).
Frequency variations in DNA copy number and
amplification events among the CMSs
The genome complexity among MSS tumors, measured as
the proportion of bases with aberrant copy numbers, varied
(median 24%, range 0–80%) and was associated to CMS
Fig. 2 DNA copy number aberrations with concomitant up- or
downregulation of gene expression. a Gene expression was sig-
nificantly higher in amplified compared to non-amplified groups in
selected recurrently amplified genes. A threshold of 5 additional copies
was used as threshold for amplification, and both broad and focal
aberrations considered in the 151 tumors where CNA and gene
expression data were available. Difference in gene expression was
assessed by Wilcoxon rank-sum tests. Colored dots indicate CMS:
yellow, CMS1; blue, CMS2; pink, CMS3; green, CMS4; purple, NA.
b A total of 2467 genes (light pink) were significantly higher
expressed in the copy number gain group compared to tumors with
neutral copy number state, while 3080 genes (light blue) were sig-
nificantly lower expressed upon copy number loss compared to tumors
with neutral copy number state. All displayed genes were significant
with FDR adjusted p < 0.05. Orange: genes that were significant in
both gain and loss analyses and accordingly had a step-wise increase in
gene expression from loss to neutral and gain; dark blue and labeled:
cancer-critical genes. c Gene expression levels according to CNA
status (loss, neutral, gain) for seven oncogenic protein kinases with a
significant upregulation of gene expression associated to copy number
gain. d The high-ploidy group was characterized by downregulation of
pathways related to metabolism and immune activation and upregu-
lation of gene signatures related to WNT signaling, cell cycle,
homologous recombination, and proliferative colon signature. e The
high-ploidy group was enriched for CMS2 tumors, shown as the
fraction of tumors belonging to each CMS subtype in the low-ploidy
and high-ploidy groups. Only CMS classified tumors are shown (n=
42 low-ploidy tumors; n= 77 high-ploidy tumors)
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(Supplementary Fig. 2c–d). CMS1 MSS had similar levels
of genome complexity as CMS2 and CMS4 (median of
35%, 33% and 27% in CMS1/2/4 respectively), but higher
levels of LOH than CMS2/4 (median of 31%, 18% and
21%, respectively). In contrast, CMS3 MSS tumors had
significantly lower levels of both CNAs and LOH compared
to MSS tumors in the remaining subtypes (median 19%, p
= 0.001 and median 12%, p= 0.03, respectively; Supple-
mentary Fig. 2d). No CNAs were exclusive for any of the
CMS groups, but there were frequency differences,
including a higher frequency of loss on 14q, 17p, and 18p
and q in CMS2 compared to CMS4 (>0.25 difference in
fraction of tumors with loss) and gain of 10p in CMS4
(18.5% of CMS4 tumors compared to 3.2% of CMS2
tumors; Fig. 3a; Supplementary Table 4 and 5).
With respect to amplifications, CMS1 MSS tumors had
frequent events on 5p (33%) and 8q (22%). The 5p
amplifications targeted HCN1 and were specific to this
subtype (although the sample number was low, n= 9; Fig.
3b). Amplifications on 13q (targeting multiple genes,
including FLT1, FLT3 and CDK8) and 20q (targeting
HNF4A and more) were found both in CMS2 and CMS4
tumors, however, 20q amplifications tended to be more
frequent in CMS2, while 13q amplifications were more
frequent in CMS4 (not statistically significant; 13q: CMS2
8%, CMS4 22%, p= 0.09; 20q: CMS2 28%, CMS4: 11%,
p= 0.1; Fisher’s exact test).
CMS2-associated gene expression profiles reflect
DNA copy number gain
To explore a potential genetic basis for CMS-associated
gene expression profiles in MSS tumors, we investigated the
overlap between genes with in cis gain/upregulation and
genes that were preferentially expressed in each CMS group
(upregulated in comparison with the remaining tumors;
limma, FDR adjusted p < 0.05 and fold change > 1.2). This
showed that CMS2 had a substantially larger fraction of
upregulated genes that were also in the gain/upregulation
category than the other CMS groups. Among CMS2-
upregulated genes, 50% were associated with copy number
gain compared to 6%, 4% and 5% in CMS1, CMS3 and
CMS4, respectively (Fig. 4a). This was also confirmed in a
larger dataset of 323 MSS TCGA tumors, where 30%, 54%,
31% and 12% of preferentially expressed genes were
associated with copy number gain in CMS1, CMS2, CMS3
and CMS4, respectively (Fig. 4a). Although the fractions of
in cis gain/upregulated genes among preferentially expres-
sed genes in CMS1/CMS3 were higher in TCGA data than
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Fig. 3 Copy number aberrations
relate to CMS (a) Frequency of
copy number gain and loss in
119 CMS classified MSS
tumors, shown according to
CMS subtype. CMS1 MSS were
excluded from the plot due to
low sample size (n= 9), gains
and losses in CMS1 MSS were
included as a separate plot in
Supplementary Fig. 1e. Blue:
CMS2, pink: CMS3, green:
CMS4. b The four CMSs
differed in the frequencies of
amplifications (≥5 additional
copies) across the genome (n=
119 MSS tumors). The length of
the chromosome bands reflects
the number of DNA segments
and does not directly represent
genomic positions. The figure
includes data from CMS1 n= 9,
CMS2 n= 61, CMS3 n= 22,
CMS4 n= 27
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CNA-rich CMS2 and CMS4 subtypes were striking in both
analyses. A potential explanation for this is the lower tumor
cell fraction of samples in the CMS4 compared to
CMS2 subtype (estimated by ASCAT; Supplementary Fig.
4b), reflecting the strong infiltration of particularly fibro-
blasts in CMS4. Separate analyses of sorted cells from four
different compartments of colon cancers (epithelial cells,
endothelial cells, fibroblasts and leukocytes; accessed from
GSE39396), showed that significant in cis gain/upregulated
genes were enriched for genes also upregulated in the
malignant epithelial cells (Fig. 4b). To address a potential
difference between malignant cells in CMS2 and CMS4,
preferentially expressed genes in CMS2 and CMS4 that
were also found upregulated in the microenvironment-
compartments (fibroblast/endothelial/leukocytes) were
excluded from the analysis, retaining 94% and 92% of
CMS2-upregulated genes and 39% and 52% of CMS4-
upregulated genes for inhouse and TCGA data, respec-
tively. The results from this analysis showed that 50% and
54% of the retained upregulated genes in CMS2 were
among the in cis gain/upregulated genes in the inhouse
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Fig. 4 CMS2-associated gene expression profiles are associated to copy number gain. a Compared to other subtypes, CMS2 tumors had a
substantially larger fraction of significant upregulated genes (limma analysis) that were also associated with copy number gain (in an in cis
manner), both in the inhouse cohort and in TCGA data. b Analyses of both inhouse and TCGA data revealed that epithelial-specific genes were
enriched among genes with significant association between in cis gain and upregulated gene expression, compared to genes preferentially
expressed in endothelial cells/leukocytes/fibroblasts. cWhen depleting the list of preferentially expressed genes of fibroblast/endothelial/leukocyte-
specific genes, the proportion of genes with significant in cis gain/upregulation remained around 50% in CMS2 and below 15% for CMS4 in both
the inhouse and the TCGA cohorts. d Left panel: We performed random sampling (n= 1000 iterations) of 20 tumors from each subtype with
subsequent pairwise calculation of the fraction of CMS-specific upregulated genes consisting of genes in the gain/upregulation category (CMS2
versus CMS3, CMS2 versus CMS4 and CMS3 versus CMS4; CMS1 was excluded due to the low sample number). Specifically, we randomly
sampled 250 differentially upregulated genes from the original results on differential gene expression (performed on all CMS classified tumors)
and calculated significant gain/upregulated genes separately for each iteration on the 40 sampled tumors. The figure shows the density distribution
of fractions calculated for the 1000 iterations. Comparing CMS2 and CMS3, CMS2 had the largest fraction of differentially upregulated genes
represented by gain/upregulated genes in all 1000 iterations. Comparing CMS2 and CMS4, CMS2 had the largest fraction of upregulated genes
represented by gain in cis genes in 99.4% of the iterations. CMS3 and CMS4 were more similar, with CMS3 having a higher fraction in 64% of the
iterations. Right panel: Random repeated sampling of 250 differentially upregulated genes and 250 gain in cis genes (n= 1000 iterations) from the
original analyses corroborated that CMS2 had a substantially higher fraction of upregulated genes represented by in cis genes compared to other
subtypes also when we controlled for the effect of different number of upregulated genes in each CMS group
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in CMS4 (Fig. 4c). Finally, the median correlations between
CNAs and gene expression were higher in the CMS2 than
CMS4 tumors (Supplementary Fig. 4c). Altogether, these
results suggest a stronger copy number-related genetic
influence on gene expression in CMS2 than in CMS4, both
within the malignant cell compartment and as a result of the
strong influence of the tumor microenvironment in CMS4.
To further confirm a significant enrichment of gain/upre-
gulation genes in CMS2 and test that this was not attributable
to the larger sample number in this subtype, we performed
random samplings (n= 1000) of 20 tumors from each CMS
group, repeating the in cis gain/upregulation analysis per
iteration (CMS1 not included due to the low frequency of
CMS1 among MSS samples). The density distributions for
the iterations showed that CMS2 had a larger proportion of
upregulated genes that were also in the gain/upregulation
category than CMS3 and CMS4 in 100% and 99.4% of the
iterations, respectively (Fig. 4d; Kolmogorov-Smirnov test
for difference in distribution, p < 2.2e-16). Additional control
analyses by modification of the approach to identify differ-
entially expressed and in cis gain/upregulation genes (out-
lined in Supplementary Fig. 5) supported the results that
CMS2-associated gene expression profiles were specifically
enriched for gain/upregulated genes (Supplementary Fig. 5).
Additionally, we addressed the potential influence of the
variable number of upregulated genes in each subtype by
repeated re-sampling of 250 gain/upregulated-category genes
and 250 of the preferentially expressed genes in each subtype.
The density distributions of the proportion of upregulated
genes that were also in the gain/upregulated category across
iterations again showed that CMS2 was enriched for copy
number-associated gene expression compared with CMS3
and CMS4 (Fig. 4d). The genes that were both upregulated in
CMS2 and belonged to the gain/upregulation category were
enriched for Reactome pathways related to the cell cycle and
DNA repair (homologous recombination and nucleotide
excision repair; Supplementary Table 6).
Consistent with the frequent 20q amplifications in CMS2, a
total of 11% of upregulated genes in CMS2 were encoded on
20q, compared with 2.4% of upregulated genes in CMS4. In
contrast, and although 13q amplifications were more frequent
in CMS4, a similar proportion of upregulated genes in CMS2
and CMS4 (4.5 and 2%, respectively) were encoded on 13q,
supporting the indication of a more direct effect of copy
number gains on gene expression in CMS2 than in CMS4.
Discussion
Successful targeting of HER2 overexpression has renewed the
interest of analyzing high-level amplifications in subgroups of
CRC [5]. Still, known amplification events are few and of low
prevalence. In this study, by integration of DNA copy number
and gene expression data, we conducted a systematic search
for amplifications with major impact on gene expression. In
addition to the well-known targets ERBB2 and MYC, we
identified novel recurrent high-level amplifications of TOX3
(16q) and CCND2 (12p) in CRC. The transcription factor
TOX3 was present at more than 23 copies in three tumors in
the inhouse dataset, and more than five copies in an additional
three tumors, totaling to a 3% amplification frequency in this
series of 203 MSS tumors. All TOX3 amplifications were
focal, and the event was associated with increased gene
expression, suggesting that TOX3 may be specifically targeted
by amplification in a small subset of CRCs. TOX3 has been
shown to protect neurons from cell death caused by stress
originating in the endoplasmic reticulum [9] and to be
amplified and overexpressed in breast cancer [10], supporting
a cancer-associated function. Furthermore, 1.5% of MSS
CRCs displayed focal amplifications (≥10 copies) of CCND2
with concordant upregulation of gene expression, and D-type
cyclins have been shown to confer tolerance to genome-
doubling in TP53 wild-type tumors [11]. Consistently, among
the three tumors affected by CCND2 amplification, one was
wild-type for TP53 and had an estimated ploidy of 4.6, while
the two TP53 mutated cancers had normal ploidy states.
Lastly, we propose ANXA11 as a target for the recurrent
(1%) amplification on 10q. The ANXA11 protein has pre-
viously been reported to be related to metastasis in CRC
[12, 13] and its downregulation has been associated with cell
cycle arrest [14]. We confirm that amplification events have
a low prevalence in CRC. Although the sample size was not
sufficient to analyze prognostic associations for each event
individually, combined analyses of ERBB2, MYC, TOX3,
CCND2, and ANXA11 indicated that high-level focal
amplification of either region was associated with a poor
survival among patients with stage I-III MSS CRCs. This
was confirmed in the somewhat larger subgroup of patients
with focal amplifications at the threshold of ≥5 additional
copies of the same regions. Furthermore, all high-level
amplifications were focal and had a more consistent rela-
tionship with gene expression than broad-range amplifica-
tions. Together, this strengthens the role for this type of
genomic aberrations in the carcinogenesis of MSS CRCs,
and investigation of the clinical relevance of the novel
recurrent events in a larger patient series is warranted.
Genome-wide, the effect of recurrent DNA copy number
gains and losses on gene expression was heterogeneous,
with a concordant in cis-relationship in less than half of the
genes with CNAs, which is in accordance with a previous
study [15]. By analyzing the data within the CMS-
framework we found that among MSS tumors, the gene
expression in CMS2 CRCs were driven by CNAs to a much
larger extent than the other subtypes, measured as the pro-
portion of upregulated genes with a significant correspon-
dence between gene expression and copy number gain. This
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was validated in the independent TCGA dataset, which
suggested that the difference was most striking between
CMS2 and CMS4, despite the similar CNA-burdens in the
two subtypes. We propose that this difference is caused by a
combination of a stronger infiltration of non-malignant cells
in the tumor microenvironment in CMS4 tumors, and a
stronger correspondence in DNA copy number/gene
expression in malignant cells in CMS2 compared to CMS4
tumors. Statistical re-sampling analyses were performed to
rule out the potential confounding effects of varying num-
bers of samples and upregulated genes in each subtype. This
finding was consistent with our hypothesis that the subtypes
primarily defined by cancer cell-intrinsic characteristics
(CMS2/3) are more directly copy number-driven than sub-
types that to a larger extent are shaped by gene expression
signals from the tumor microenvironment (CMS1/4). While
these analyses do not directly explain why CMS2-related gene
expression patterns are more closely associated with CNAs
than CMS3-related gene expression, gene set analyses sup-
ported that the cell cycle activity characteristic of CMS2 is at
least partly explained by DNA copy numbers, and the gen-
erally lower CNA burden in CMS3 may be a part of the
explanation. Additional functional analyses are needed to
confirm that CMS2 tumors are indeed specifically driven by
CNAs, and there are limitations to our approach. For example,
it has previously been shown that integration of DNA and
RNA-level data favors the identification of genes that are more
strongly regulated by CNAs than other mechanisms [16],
indicating technical bias in the analyses. However, and despite
the similar frequencies of CNAs and amplifications in CMS2
and CMS4, our findings may also strengthen the hypothesis
that mechanisms other than CNAs have greater importance
when it comes to modulating gene expression in the
mesenchymal CMS4 subtype. Consequently, we propose that
investigation of the functional and clinical consequence of
CNAs in larger patient series may benefit from consideration
of the transcriptional phenotype within which they occur.
In conclusion, we identify several recurrent high-level
amplifications with a major impact on gene expression in
MSS CRC, including the known and targetable ERBB2, but
also novel amplicons such as TOX3 and ANXA11. We also
propose that the epithelial/canonical subtype CMS2 has a
stronger copy number-related genetic basis than subtypes




A total of 265 stage I-IV primary CRCs were collected at
Oslo University Hospital – Aker (OUH series) in the period
of December 2005 to March 2009 and Stavanger University
Hospital (SUH series) in the period of June 2003 to
November 2009. The OUH series comprised 201 tumor
samples from a consecutive study. The SUH series com-
prised 64 tumors and was intentionally enriched for MSI+
tumors (Supplementary Table 2). Principal component
analysis of copy number data indicated no systematic dif-
ferences between the series, and they were consequently
analyzed together (Supplementary Fig. 6a).
Of totally 265 collected samples, 257 samples (53 MSI, 1
MSS POLE mutated and 203 MSS samples) were included
for downstream analyses (samples with failed ASCAT
segmentation, n= 2; low tumor percent, n= 2; and incon-
clusive MSI analyses, n= 4 were excluded). Gene expres-
sion data was available for all CRCs in the OUH series that
were not treated with preoperative chemoradiotherapy (n=
189). Pre-operative treatment did not have a major impact
on the CNA data (assessed by principal component analy-
sis, PCA; Supplementary Fig. 6a).
The study was approved by the Regional Committee for
Medical and Health Research Ethics, South East Norway
(project ID: 1.2005.1629) and the Regional Committee for
Medical and Health Research Ethics, West Norway (project
ID: 197.04). All patients provided written informed consent,
and the study was conducted in accordance with the
Declaration of Helsinki.
DNA and RNA extraction and MSI analysis
DNA and RNA were extracted using the Qiagen AllPrep
DNA/RNA Mini kit (Qiagen, Hilden, Germany) according to
manufactures recommendations. Briefly, tissue was homo-
genized and lysed using the Qiagen TissueRuptor and DNA
and RNA was extracted using spin columns. One extra cycle
of washing was performed for removal of residual buffer
before elution of DNA and concentration and ratios were
measured with Nanodrop (Thermo Fisher, Waltham, MA,
USA). MSI status was determined by analyses of the BAT-
25/BAT-26 mononucleotide loci, according to procedures
previously described [17]. Seven samples had uncertain MSI
status, two of which were determined by additional analyses
using the MSI Analysis System, version 1.2 (Promega,
Fitchburg, WI, USA), and one sample was grouped as an
MSS due to its complex copy number profile. The remaining
four samples were excluded from group analyses. Analyses of
POLE mutation status has previously been performed for the
OUH samples [18], and one POLE mutated MSS tumor was
grouped with MSI tumors for all subgroup analyses.
DNA copy number analysis
Copy number data were generated using Affymetrix
Genome-Wide SNP6.0 arrays according to recommended
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procedures and as previously described [19]. In short,
500 ng of DNA in low-EDTA TE-buffer was digested,
adapter ligated, diluted, amplified and quality controlled by
gel electrophoresis (4% TBE gel, Lonza, Basel, Switzer-
land). Samples were purified using AMPure XP beads
(Beckman Coulter, Brea, CA, USA) and further fragmented
and quality controlled by gel electrophoresis (2% TBE gel,
Lonza) prior to labelling, denaturation and hybridization
onto arrays for 16–18 h. Hybridized samples were washed,
stained and scanned, and quality cut-offs of CQC > 0.4 and
MAPD < 0.34 were set for inclusion of samples into the
final dataset. Resulting CEL files were pre-processed using
PennCNV-Affy using Affymetrix Power Tools version
1.15.0 as previously described [20].
Segmentation of individual samples was performed by
two methods: i) by the PCF algorithm implemented in the R
package copynumber (version 1.16.0 and R version 3.4.0)
[21] with gamma parameter 100, and ii) by the ASCAT
algorithm (version 2.4.4 and R version 3.3.2) [22] with
penalty parameter 50. Relative copy numbers (mean LogR
ratios) from PCF were used to calculate the percentage of
genome affected by gain and loss, for genome wide gain/
loss frequencies across sample groups, for GISTIC analysis,
and for integration of copy number gain/loss and gene
expression data). Allele-specific ASCAT data (whole gene
copies) were used to analyze amplifications and LOH, and
for estimation of ploidy. Chromosomes X and Y were
disregarded from analyses.
The PCF data was median centered within each sample
prior to downstream analyses, and PCF values of 0.15/-0.15
were used as threshold for calling copy number gain and loss.
All downstream analyses were run using R version 3.4.1.
The fraction of the genome with aberrant copy number/
LOH was calculated as the number of aberrant bases out of
the total number of bases with copy number/LOH estimate
available. The PCF and ASCAT data had good concordance
in estimation of the fraction of the genome affected by gain/
loss among the samples (Supplementary Fig. 6b). Amplifi-
cations were called from ASCAT data as total copy num-
bers (nAB) more than five copies above the sample-wise
genome-wide median copy number as estimated by
ASCAT. LOH was defined when nA or nB was zero and the
remaining allele was non-zero.
GISTIC analysis (version 2.0.23) was performed using
default parameters, except for ta/td 0.15, brlen 0.7, maxseg
2000, conf 0.99, genegistic 1, broad 1, and savegene 1.
Significant regions based on an FDR adjusted p-value (i.e.,
q-value) threshold of 0.25 were reported.
Gene expression analysis
Gene expression data obtained using exon-level Affymetrix
GeneChip Human Exon 1.0 ST arrays and pre-processed
according to RMA, have previously been published for the
OUH series (GSE24550, GSE29638, GSE69182) [23].
Transcript clusters with missing gene symbols were exclu-
ded, and genes with annotations from different databases
were reduced to one entry per gene by prioritizing accord-
ing to RefSeq, ENSEMBL, UCSC genes, Genbank and
GenbankHTC. Gene symbols were checked by the multi-
symbol checker available from the HUGO Gene Nomen-
clature Committee (HGNC) to ensure that the current gene
symbols were used, for proper alignment with the CNA
dataset [24]. Differential gene expression analysis was
performed with the R package limma (version 3.32.10).
Differences in gene set scores between groups for 66 gene
sets (MSigDB v6.1) relevant for CRC or chromosomal
instability were assessed by the R package GSA (version
1.03; Supplementary Table 7) and gene sets with p-values <
0.2 were reported. Reactome pathway enrichment analysis
was done using the PANTHER Overrepresentation test in
the online PANTHER tool [25] with Reactome version 58
[26].
The samples have previously been classified according to
CMS using the classifyCMS.RF function in the R package
CMSclassifier, with default posterior probability threshold
[27]. Confident classification was obtained for 149 samples
in the OUH series, 119 of which were MSS (Supplementary
Fig. 7a).
Integration of gene expression and DNA copy
number data
Integration of DNA copy number and gene expression data
was performed for 151 MSS from the OUH series (Sup-
plementary Fig. 7b). Genes were assigned copy number
values from PCF segmented data by mapping hg19 genome
coordinates to transcripts as annotated in the R package
TxDb.Hsapiens.UCSC.hg19.knownGene (version 3.2.2)
using the findOverlaps function from the GenomicRanges
package (version 1.28.4). Genes with conflicting copy
number values along the gene, i.e. spanning segment
breakpoints were handled as follows: (i) genes where all
segments were called with either loss or gain kept the most
extreme copy number estimate, (ii) genes where all seg-
ments were copy number neutral were assigned the median
PCF value of those segments, (iii) genes that ranged
between neutral copy number and gain or loss were called
as aberrant (kept the most extreme value), and (iv) genes
with both gain and loss were set to NA for that particular
sample. Prior to integration analyses, genes with expression
variance of <0.1 across samples were excluded. Gene
expression was compared between samples in different
copy number groups (copy number gain versus neutral copy
number, or loss versus neutral copy number) using Wil-
coxon rank-sum tests (two-sided) and a significance
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threshold of FDR corrected p < 0.05 (genes with <10 sam-
ples in each copy number group were not considered). The
p.adjust function implemented in the R stat package was
used for FDR correction. In cis-association between gene
expression and copy number was called only for genes that
also had a positive correlation between gene expression and
copy number from Spearman’s test (Spearman’s rho > 0 and
FDR corrected p < 0.05).
Correspondence between gene amplification and
expression was assessed in two ways. First, for an ampli-
fication peak-oriented approach of focal amplifications
only, we determined whether at least one gene in each
amplified peak had outlier gene expression, defined as
expression levels higher than 1.5 times the interquartile
range above the third quartile of all 151 MSS tumors.
Second, for a gene-focused analysis of both broad and focal
amplifications, we investigated the effect of amplification
events (≥5 additional copies) found recurrently (≥2 tumors)
across the MSS cohort, for genes with gene expression
variance of >0.1. Genes were identified as having an in cis-
association if at least 50% of the amplified tumors were
among the top [1.5*tumors with amplification] samples on
gene expression (or among top five samples on gene
expression when fewer than five samples displayed ampli-
fication). Similar correspondence analyses were also per-
formed for recurrent high-level amplifications, defined as
≥15 additional copies in >1 tumor. For selected amplified
genes the gene expression was additionally assessed by
Wilcoxon tests (amplified versus non-amplified groups,
both broad and focal amplifications of ≥5 additional copies
considered as amplified).
To investigate a potential enrichment of genes with in
cis-association (gain/upregulation) among upregulated
genes in each of the four CMSs we identified differentially
expressed genes between each subtype and the remaining
subtypes using limma (FDR adjusted p < 0.05 and fold
change > 1.2) and calculated the proportion of upregulated
genes that overlapped with in cis genes. To control for the
potential impact of different numbers of samples in the
subtypes, we performed random sampling (n= 1000) of 20
tumors from each CMS group and repeated analyses for
each iteration. Enrichment was assessed in pairwise com-
parisons among the subtypes. For a gene to be assessed in
the in cis analysis, at least three tumors had to be found in
the copy number gain and copy number neutral group. For
robustness, the analysis was done in three different ways: (i)
by identifying significant in cis genes (gain/upregulation,
Wilcoxon rank-sum tests) for the 40 tumors (20 tumors in
each of the subtypes included in the pairwise comparison)
and performing differential expression analysis (limma;
FDR adjusted p < 0.05 and fold change > 1.2) for the 20
versus 20 tumors per re-sampling, (ii) by identifying sig-
nificant gain/upregulated genes for the 40 tumors per re-
sampling and using the differential expression results from
the original analyses including all samples, and (iii) by
identifying significant in cis genes for the 40 tumors and
randomly sampling 250 genes from the original differential
expression results. Furthermore, to test if the variable
number of genes that were differentially upregulated in each
subtype affected the analysis we also performed repeated (n
= 1000) re-samplings of 250 genes from the original gain/
upregulated gene list and among the genes originally found
to be upregulated in each CMS group (CMSx versus
remaining CMS classified tumors).
TCGA validation analyses
To validate both the nominated high-level DNA amplifi-
cations and CMS-related associations between CNAs and
gene expression, 323 MSS tumors from the TCGA colon/
rectal tumor dataset with both data types available were
analyzed. The CNA data was downloaded as raw CEL files
and analyzed with the same analysis pipeline used for
analyses of the inhouse data. Matching gene expression data
(RSEM-normalized values) were used for integration ana-
lyses with CNAs. Prior to data integration, the same fraction
of low-variance genes as in the inhouse dataset was
excluded prior to Wilcoxon-testing. The amplification ana-
lyses (based on allele-specific ASCAT segmented data)
were performed on 320 out of 323 tumors due to segmen-
tation failure in 3 samples.
Contribution of different CRC cell compartments
Gene expression data from four different colon cancer cell
populations (epithelial cells, endothelial cells, fibroblasts
and leukocytes; GSE39396 [28], isolated from tumors using
Fluorescence Activated Cell Sorting) was included in the
analyses to investigate the contribution of different cell
compartments to the preferentially upregulated genes in the
CMS groups and the significant in cis gain/upregulated
genes. Differential gene expression analyses were per-
formed using limma, as described above.
Survival analyses
Survival analyses were performed for patients with stage I-
III MSS CRCs (n= 174; Supplementary Table 2). Five-year
overall survival was used as endpoint, evaluating time from
surgery to death from any cause. Patients without an event
were censored at 5 years. Kaplan-Meier plots were gener-
ated with the ggsurvplot function in the R package surv-
miner. The survdiff function in the R package survival was
used for log rank tests. Univariable and multivariable Cox
proportional hazards analyses were performed with the
coxph function implemented in the R package survival. For
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multivariable analyses, age (above/below median), gender,
tumor localization (distal/proximal) and stage were included
as variables.
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